Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/834
Title: Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Authors: Santos González, Jesús L
Palacios Muñoz, Rosario
Lozano, Fernando
López, Manuel
Gálvez, María Carmen
de las Torres, Javier
López-Cortés, Luis Fernando
Ríos, María José
Rivero Román, Antonio
metadata.dc.contributor.authoraffiliation: [Santos González,JL; Palacios Muñoz,R] Hospital Universitario Virgen de la Victoria, Málaga, Spain. [Lozano,F] Hospital de Valme, Sevilla, Spain. [López,M] Hospital Virgen de las Nieves, Granada, Spain. [Gálvez,MC] Hospital Torrecárdenas, Almería, Spain. [las Torres,J de] Hospital Costa del Sol, Marbella, Spain. [López-Cortés,LF] Hospital Virgen del Rocío, Sevilla, Spain. [Ríos,MJ] Hospital Virgen Macarena, Sevilla, Spain. [Rivero Román,A] Hospital Reina Sofía, Córdoba, Spain.
metadata.dc.contributor.group: Grupo andaluz para el estudio de las enfermedades infecciosas (GAEI)
Keywords: Benzoxazinas;Lamivudine;Efavirenz;Didanosina;Fármacos Anti-VIH;Quimioterapia Combinada;Estudios de Seguimiento;Humanos;Adulto;Infecciones por VIH;VIH-1;Carga Viral;Inhibidores de Transcriptasa Inversa;Resultado del Tratamiento
metadata.dc.subject.mesh: Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Anti-HIV Agents
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Oxazines::Benzoxazines
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 2-Ring::Purines::Purine Nucleosides::Inosine::Didanosine
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Drug Therapy, Combination
Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Follow-Up Studies
Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
Medical Subject Headings::Organisms::Viruses::RNA Viruses::Retroviridae::Lentivirus::Lentiviruses, Primate::HIV::HIV-1
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Pyrimidines::Pyrimidine Nucleosides::Cytidine::Deoxycytidine::Zalcitabine::Lamivudine
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Nucleic Acid Synthesis Inhibitors::Reverse Transcriptase Inhibitors
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Microbiological Techniques::Viral Load
Adult
Issue Date: 15-Jan-2008
Publisher: Mary Ann Liebert
Citation: Santos J, Palacios R, Lozano F, López M, Gálvez MC, de la Torres J, et al. Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up. AIDS Res. Hum. Retroviruses. 2008 ; 24(1):24-6
Abstract: The aim of this study was to evaluate the long-term efficacy and safety of didadosine (ddI), lamivudine (3TC), and efavirenz (EFV). This was a follow-up to the VESD study, a 12-month open-label, observational, multicenter study of adult patients with HIV infection who started antiretroviral treatment with the ddI-3TC-EFV once-daily regimen. Of the 167 patients originally included, 106 patients remained on the same triple therapy at the end of the study (1 year), and they were offered an extra 24 months of follow-up; 96 were enrolled in this study (VESD-2). Seventy patients out of the initial cohort were still on the same regimen at month 36, with 97% of them with plasma viral load <50 copies /ml. An intention-to-treat analysis showed that the percentage of patients with plasma viral load <50 copies/ml was 73% at 36 months. CD4 cell counts increased 344 cells/microl over the 36 months. Safety and tolerance were good with no unexpected long-term toxicity. After 3 years of treatment with ddI-3TC-EFV, more than 40% of the patients were still receiving the initial antiretroviral therapy with sustained, durable immunovirological benefit and good acceptance. Long-term toxicity and virological failure were low.
Description: Clinical Trial; Journal Article; Multicenter Study;
URI: http://hdl.handle.net/10668/834
metadata.dc.relation.publisherversion: http://online.liebertpub.com/doi/abs/10.1089/aid.2007.0142
metadata.dc.identifier.doi: 10.1089/aid.2007.0142
ISSN: 0889-2229 (Online)
Appears in Collections:01- Artículos - APES Costa del Sol
01- Artículos - Complejo Hospitalario Torrecárdenas
01- Artículos - Hospital de Valme
01- Artículos - Hospital Reina Sofía
01- Artículos - Hospital Virgen de la Victoria
01- Artículos - Hospital Virgen de las Nieves
01- Artículos - Hospital Virgen del Rocío
01- Artículos - Hospital Virgen Macarena

Files in This Item:
File Description SizeFormat 
Santos_Long.pdfArtículo publicado59,17 kBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons